Provided by:
HIV Grand Rounds from the University of
Pennsylvania School of Medicine
Academic Year 2014-2015
“Progressive Multifocal Leukoencephalopathy: Lessons from AIDS and Natalizumab”
Thursday, November 13 2014
12:00 PM – 1:00 PM (EDT)
JMB Class of 1962 Auditorium
Joseph Berger, MD
Professor of Neurology
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Target Audience
This program has been designed for departmental/institutional faculty, fellows, residents, medical students, nurses and
community physicians in the medical specialties of HIV, infectious disease, internal medicine, family practice,
dermatology, osteo-specialists, nephrology, hematology/oncology, psychiatry, public health, and Ob/Gyn.
Educational Objectives
After completing this activity, participants should be able to:
 Apply in clinical practice approaches for preventing HIV infection and getting newly diagnosed patients into care

Individualize ARV therapy for the treatment –naïve and treatment-experienced patients

Manage the aging patient with HIV infection, including issues associated with cardiovascular and bone disease
Accreditation
The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA
PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in
the activity.
Acknowledgement of Commercial Support*
Gilead Sciences Medical Affairs, Janssen Therapeutics, Division of Janssen Products, LP, ViiV Healthcare
For more information, please contact
Richard Gordon
847-951-5318
rgordon@viraled.com
Check your CME online at www.penncmeonline.com
Disclosure of Relevant Financial Relationships and Unapproved Uses of Products
It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to
control the content of an educational activity to disclose to the learners all relevant financial relationships that they have
with any commercial interest that provides products or services that may be relevant to the content of this continuing
medical education activity. For this purpose we consider relationships of the person involved in the CME activity to
include financial relationships of a spouse or partner.
The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from
involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in
improving medical practice, are based on valid content, and are independent of control from commercial interests and
free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure
information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest
relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically
rigorous and evidence-based presentations.
The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania, Mila Kostic,
Director of CME and the peer reviewer Zalman Agus, MD, Associate Dean for CME, have disclosed that they have
no relevant financial relationships with any commercial interests related to the content of this educational activity.
The following individuals have disclosed that they have no relevant financial relationships with any commercial interests
related to the content of this educational activity:
PLANNING COMMITTEE MEMBER NAME
BRIAN BOYLE, MD
MILA KOSTIC
RICK GORDON
MICHAEL SCHOEN, PHD
OLIVER FULTZ
The following individuals have reported the listed relevant financial relationships with commercial interests related to
the content of this educational activity.
PLANNING COMMITTEE MEMBER NAME NAME OF COMMERCIAL INTEREST
RELATIONSHIP
IAN FRANK, MD
GILEAD, VIIV
ADVISORY BOARD
JANSSEN
CONSULTANT
GLAXOSMITHKLINE, BAVARIAN NORDIC
RESEARCH GRANT
CALVIN COHEN, MD
GILEAD, BMS, JANSSEN
RESEARCH GRANT/ADVISORY BOARD
VIIV, MERCK
ADVISORY BOARD
GILEAD
TESTIMONY
PRESENTER NAME
JOSEPH BERGER, MD
NAME OF COMMERCIAL INTEREST
AMGEN; ASTRA ZENECA; BMS; EISAI; JANSSEN
MILLIENNIUM; PAREXEL; PFIZER; ROCHE; TAKEDA
GENENTECH; GENZYME; INCYTE; INHIBIKASE
JOHNSON & JOHNSON; NOVARTIS
PML CONSORTIUM; BIOGENIDEC
RELATIONSHIP
PML ADJUDICATION COMMITTEE
PML ADJUDICATION COMMITTEE
CONSULTANT
CONSULTANT
GRANT (TO INSTITUTION)
Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary,
royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership
interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as
employment, management position, independent contractor (including contracted research), consulting, speaking and teaching,
membership on advisory committees or review panels, board membership, and other activities from which remuneration is received
or expected